Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesRetinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaNeuroblastomaIntegrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaTargeted immunotherapy for pediatric solid tumorsInvolvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based ImmunotherapyTranslational development of difluoromethylornithine (DFMO) for the treatment of neuroblastomaCancer Stem Cells and Their Interaction with the Tumor Microenvironment in NeuroblastomaDysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsTrial Watch: Adoptive cell transfer for oncological indicationsImmunotherapy of Childhood SarcomasEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityAntibody-based immunotherapy of solid cancers: progress and possibilitiesNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyNatural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approachesApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsHDAC inhibitors and immunotherapy; a double edged sword?Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapyPrimer on tumor immunology and cancer immunotherapyNeuroblastoma: issues in transplantationCellular immunotherapy for pediatric solid tumorsChildren's Oncology Group's 2013 blueprint for research: bone tumorsInhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticlesIn silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive TumorsThe ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Protein glycosylation in cancers and its potential therapeutic applications in neuroblastomaImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesTL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRIAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersCommon variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastomaEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Overview and recent advances in the treatment of neuroblastoma.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastomaOxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
P2860
Q21131216-CD2986CC-FEB3-428C-9EE7-EA0DD9D4100FQ24186451-8788D192-F580-4C54-8CFD-F0E566243409Q24186636-FB2103E5-ABE1-4B60-B61E-38D4A036B646Q24200296-8082F2AC-70AE-43FE-BBD6-14CAB765228CQ24310296-956C16CC-330A-42D0-BFB9-C233FEC15B41Q24617733-9329A0C1-F02F-4EEA-98D5-01096D4F6304Q24630017-4C9E7BC5-D9F0-4D3C-8BA5-86A4A0CDBD67Q26747703-FAA8F7AE-5C29-4DCE-8D12-70F1FA1AB019Q26765594-8AC05C32-99D1-40CD-B611-41EED647CA55Q26770306-A3542A2A-9E1D-4F75-BE55-EC1F0A41B021Q26771238-DA3AD5C1-3533-49DB-8DFD-6598CF732434Q26771367-5FCED285-86CC-47EA-97B2-9E4C84161104Q26785545-86BDD6D0-95B3-4169-825E-6BBE7F37182BQ26795369-9AAF91B5-25D6-41C2-84BF-2A3731AB1BF0Q26796313-CBB7A2E8-AF09-435B-99ED-D48F61D35AF3Q26796542-BBFA6988-EDF6-48C5-B2D8-6FF6719BB1DFQ26797345-0791E95C-3A01-425E-8E23-4EE68E81D222Q26825652-8520F427-3D23-4D36-A6DA-9EAAF4AE6195Q26852287-1CAAB51C-3D2B-4A4A-855F-5B074DBE0BF5Q26853102-23F37081-64C2-446C-A792-32FC774391D3Q26993238-38BAB085-7360-4452-9748-16947C7ED071Q27001126-D48CF9AC-B5BA-4368-BD24-9C2C2D1DF43DQ27008197-18125C35-D04F-4001-802B-6980170EB31DQ27014912-D3212FCB-5382-49DD-B47E-B3900AB3CD10Q27027664-50E6F6ED-CFE5-471E-AC8D-43EF3CA194E4Q27301841-36B24E8B-584A-4F2D-B365-6A689960A896Q27678257-6A6D509E-70C6-43A5-959D-B2B2651A303DQ27853241-109FE84D-4E6D-4587-8961-32315C33FDEEQ28069952-E021948E-A6F3-48F7-8DA9-12F7625C7C0DQ28079180-3F04B931-5195-4C50-B37B-83B0C870BB64Q28540575-B15BE0E9-DF26-40BB-A440-32043FE73F09Q28551080-9851F711-59E3-46B9-837C-89F93E7F4040Q28943271-9E59A371-AFCF-40FE-9518-DC69385C4933Q30234441-4993F19C-6250-4CE0-A8A5-C9A4F0DCAE7DQ30238693-8A630804-59B8-4C4D-B062-131B5B30BECBQ30916013-C481875B-5D41-4D04-9694-8E624A4C4077Q33394925-43812EF1-D99F-4320-8FC9-E39D8218C4EEQ33408675-B9A5779E-5FD7-484A-9595-A745962C328DQ33419558-CAFB8115-9692-4E04-991E-FF2B4402E98FQ33424231-D30D4933-339F-4A53-9A17-4912FA3A8F84
P2860
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@ast
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@en
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@nl
type
label
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@ast
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@en
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@nl
prefLabel
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@ast
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@en
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@nl
P2093
P2860
P50
P3181
P356
P1476
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
@en
P2093
Allen Buxton
Andrew L Gilman
Barry Anderson
Children's Oncology Group
Helen X Chen
Hiro Shimada
John M Maris
Judith G Villablanca
Katherine K Matthay
M Fevzi Ozkaynak
P2860
P304
P3181
P356
10.1056/NEJMOA0911123
P407
P577
2010-09-01T00:00:00Z